Pancreatic Cancer
Pancreatic Cancer
Advertisement
Joseph McCollom, DOPancreatic Cancer | June 4, 2025
Dr. Joseph McCollom discusses his path to specialization in GI cancers and the pivotal role of palliative care in oncology.
Devalingam Mahalingam, PhDPancreatic Cancer | June 2, 2025
Dr. Mahalingam shares preliminary results from the randomized phase 2 study of elraglusib with gemcitabine/nab-paclitaxel.
Lauren Dembeck, PhDPancreatic Cancer | June 2, 2025
A post hoc analysis of the NAPOLI 3 trial offers insight into prolonged survival in mPDAC.
Lauren Dembeck, PhDPancreatic Cancer | June 2, 2025
A therapy has shown a statistically significant OS benefit in patients with unresectable locally advanced pancreatic cancer.
Zachary BessettePancreatic Cancer | June 2, 2025
Results of CASSANDRA may alter the standard of care for patients with resectable PDAC.
Michele Reni, MDPancreatic Cancer | June 1, 2025
Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III PDAC.
Lauren Dembeck, PhDPancreatic Cancer | May 29, 2025
The Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and shows encouraging efficacy in patients with PDAC.
Emily MenendezPancreatic Cancer | May 21, 2025
The phase 3 NEOPAN study has shown that FOLFIRINOX can significantly improve PFS compared with gemcitabine.
Jessica GangaPancreatic Cancer | May 16, 2025
Researchers evaluated the use of mFOLFIRINOX for the treatment of patients with resectable pancreatic adenocarcinoma.
Bassel El-Rayes, MDPancreatic Cancer | April 29, 2025
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
James Cleary, MD, PhDPancreatic Cancer | April 17, 2025
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Emily MenendezPancreatic Cancer | April 15, 2025
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Stephen Liu, MDPancreatic Cancer | April 15, 2025
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Stephen Liu, MDPancreatic Cancer | April 15, 2025
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
Emily MenendezPancreatic Cancer | March 18, 2025
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Elizabeth Auckley, MDPancreatic Cancer | February 14, 2025
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
Elizabeth Auckley, MDPancreatic Cancer | February 14, 2025
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
Elizabeth Auckley, MDPancreatic Cancer | February 14, 2025
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Jonathan Strosberg, MDPancreatic Cancer | January 29, 2025
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response.
Shubham Pant, MDPancreatic Cancer | March 19, 2025
Dr. Pant shared updates on a phase 1b dose escalation trial of gemcitabine, nab-paclitaxel, and lixumistat.
Advertisement